2018年胰腺癌研究及诊疗新进展
|
摘要
胰腺癌是一种发病隐匿、进展快、疗效不佳、中位生存期短、预后极差的一种恶性肿瘤,素有"癌中之王"的称号。随着居民生活水平的提高和临床检出率的提升,近年来胰腺癌的发病率呈现逐年增长的趋势,成为威胁居民健康水平的重要因素。随着基础研究和临床研究的深入,胰腺癌的分子机制和临床分型特点越来越清晰,为攻克"癌王"提供了理论上的依据。本文对2018年胰腺癌的重大研究进展进行综述。
Pancreatic cancer is a highly lethal disease, for which mortality closely parallels incidence. Most patients remain asymptomatic, and the disease progresses rapidly. Due to economic development and improvement of clinical detection rate, incidence of pancreatic cancer is roaring, which becomes a serious health problem. Thanks to the development of basic and clinical research, more detailed information is obtained on pancreatic cancer, providing theoretical support for conquering "the king of cancer". This review summarized recent high quality studies on pancreatic cancer.
Pancreatic cancer is a highly lethal disease, for which mortality closely parallels incidence. Most patients remain asymptomatic, and the disease progresses rapidly. Due to economic development and improvement of clinical detection rate, incidence of pancreatic cancer is roaring, which becomes a serious health problem. Thanks to the development of basic and clinical research, more detailed information is obtained on pancreatic cancer, providing theoretical support for conquering "the king of cancer". This review summarized recent high quality studies on pancreatic cancer.
引文
[1]FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-E386.
[2]RAHIB L,SMITH B D,AIZENBERG R,et al.Projecting cancer incidence and deaths to 2030:the unexpected burden of thyroid,liver,and pancreas cancers in the United States[J].Cancer Res,2014,74(11):2913-2921.
[3]KIRKEGARD J,CRONIN-FENTON D,HEIDE-JORGENSENU,et al.Acute pancreatitis and pancreatic cancer risk:a nationwide matched-cohort study in Denmark[J].Gastroenterology,2018,154(6):1729-1736.
[4]SADR-AZODI O,OSKARSSON V,DISCACCIATI A,et al.Pancreatic cancer following acute pancreatitis:a populationbased matched cohort study[J].Am J Gastroenterol,2018,113(11):1711-1719.
[5]ANTWI S O,FAGAN S E,CHAFFEE K G,et al.Risk of different cancers among first-degree relatives of pancreatic cancer patients:influence of probands’susceptibility gene mutation status[J].J Natl Cancer Inst,2018.[Epub ahead of print]
[6]JIAO L,CHEN L,WHITE D L,et al.Low-fat dietary pattern and pancreatic cancer risk in the women’s health initiative dietary modification randomized controlled trial[J].J Natl Cancer Inst,2018,110(1).
[7]SHARMA A,SMYRK T C,LEVY M J,et al.Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis[J].Gastroenterology,2018,155(2):490-500.
[8]SETIAWAN V W,STRAM D O,PORCEL J,et al.Pancreatic cancer following incident diabetes in African Americans and Latinos:the multiethnic cohort[J].J Natl Cancer Inst,2018.[Epub ahead of print]
[9]SHARMA A,KANDLAKUNTA H,NAGPAL S,et al.Model to determine risk of pancreatic cancer in patients with new-onset diabetes[J].Gastroenterology,2018,155(3):730-739.
[10]FAN X,ALEKSEYENKO A V,WU J,et al.Human oral microbiome and prospective risk for pancreatic cancer:a population-based nested case-control study[J].Gut,2018,67(1):120-127.
[11]KHALAF N,YUAN C,HAMADA T,et al.Regular use of aspirin or non-aspirin nonsteroidal anti-inflammatory drugs is not associated with risk of incident pancreatic cancer in two large cohort studies[J].Gastroenterology,2018,154(5):1380-1390.
[12]SHEEL A,HARRISON S,SARANTITIS I,et al.Identification of cystic lesions by secondary screening of familial pancreatic cancer(FPC)kindreds is not associated with the stratified risk of cancer[J].Am J Gastroenterol,2018.[Epub ahead of print]
[13]CANTO M I,ALMARIO J A,SCHULICK R D,et al.Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance[J].Gastroenterology,2018,155(3):740-751.
[14]HU C,HART S N,POLLEY E C,et al.Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer[J].JAMA,2018,319(23):2401-2409.
[15]NIMMAKAYALA R K,SESHACHARYULU P,LAKSHMANANI,et al.Cigarette smoke induces stem cell features of pancreatic cancer cells via PAF1[J].Gastroenterology,2018,155(3):892-908.
[16]MUELLER S,ENGLEITNER T,MARESCH R,et al.Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes[J].Nature,2018,554(7690):62-68.
[17]LIU M,YANG J,ZHANG Y,et al.ZIP4 promotes pancreatic cancer progression by repressing ZO-1 and claudin-1 through a ZEB1-dependent transcriptional mechanism[J].Clin Cancer Res,2018,24(13):3186-3196.
[18]ANDRICOVICH J,PERKAIL S,KAI Y,et al.Loss of KDM6Aactivates super-enhancers to induce gender-specific squamouslike pancreatic cancer and confers sensitivity to BET inhibitors[J].Cancer Cell,2018,33(3):512-526.
[19]WANG F,XIA X,YANG C,et al.SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy[J].Clin Cancer Res,2018,24(13):3176-3185.
[20]HENRY K E,DACEK M M,DILLING T R,et al.A PETimaging strategy for interrogating target engagement and oncogene status in pancreatic cancer[J].Clin Cancer Res,2018,25(1):166-176.
[21]HEINING C,HORAK P,UHRIG S,et al.NRG1 fusions in KRAS wild-type pancreatic cancer[J].Cancer Discov,2018,8(9):1087-1095.
[22]DANAI L V,BABIC A,ROSENTHAL M H,et al.Altered exocrine function can drive adipose wasting in early pancreatic cancer[J].Nature,2018,558(7711):600-604.
[23]RENZ B W,TAKAHASHI R,TANAKA T,et al.Beta2 Adrenergic-neurotrophin feedforward loop promotes pancreatic cancer[J].Cancer Cell,2018,33(1):75-90.
[24]LIANG C,SHI S,LIU M,et al.PIN1 maintains redox balance via the c-Myc/NRF2 axis to counteract Kras-induced mitochondrial respiratory injury in pancreatic cancer cells[J].Cancer Res,2019,79(1):133-145.
[25]PUSHALKAR S,HUNDEYIN M,DALEY D,et al.The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression[J].Cancer Discov,2018,8(4):403-416.
[26]BERNARD V,SEMAAN A,HUANG J,et al.Single cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression[J].Clin Cancer Res,2018.[Epub ahead of print]
[27]POMMIER A,ANAPARTHY N,MEMOS N,et al.Unresolved endoplasmic reticulum stress engenders immune-resistant,latent pancreatic cancer metastases[J].Science,2018,360(6394):4908.
[28]YANG A,HERTER-SPRIE G,ZHANG H,et al.Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms[J].Cancer Discov,2018,8(3):276-287.
[29]TIRIAC H,BELLEAU P,ENGLE D D,et al.Organoid profiling identifies common responders to chemotherapy in pancreatic cancer[J].Cancer Discov,2018,8(9):1112-1129.
[30]KNUDSEN E S,BALAJI U,MANNAKEE B,et al.Pancreatic cancer cell lines as patient-derived avatars:genetic characterisation and functional utility[J].Gut,2018,67(3):508-520.
[31]MELLBY L D,NYBERG A P,JOHANSEN J S,et al.Serum biomarker signature-based liquid biopsy for diagnosis of earlystage pancreatic cancer[J].J Clin Oncol,2018,36(28):2887-2894.
[32]FAHRMANN J F,BANTIS L E,CAPELLO M,et al.A plasmaderived protein-metabolite multiplexed panel for early-stage pancreatic cancer[J].J Natl Cancer Inst,2018.[Epub ahead of print]
[33]JABBAR K S,ARIKE L,VERBEKE C S,et al.Highly accurate identification of cystic precursor lesions of pancreatic cancer through targeted mass spectrometry:a phaseⅡc diagnostic study[J].J Clin Oncol,2018,36(4):367-375.
[34]FRANKLIN O,JONSSON P,BILLING O,et al.Plasma microRNA alterations appear late in pancreatic cancer[J].Ann Surg,2018,267(4):775-781.
[35]SANDINI M,PATINO M,FERRONE C R,et al.Association between changes in body composition and neoadjuvant treatment for pancreatic cancer[J].JAMA Surg,2018,153(9):809-815.
[36]HE J,BLAIR A B,GROOT V P,et al.Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?[J].Ann Surg,2018,268(1):1-8.
[37]GEMENETZIS G,GROOT V P,BLAIR A B,et al.Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection[J].Ann Surg,2018.[Epub ahead of print]
[38]JANG J Y,HAN Y,LEE H,et al.Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer:a prospective,randomized,open-label,multicenter phase 2/3trial[J].Ann Surg,2018,268(2):215-222.
[39]MAJUMDER S,PHILIP N A,NAGPAL S,et al.High-grade dysplasia in resected main-duct intraductal papillary mucinous neoplasm(MD-IPMN)is associated with an increased risk of subsequent pancreatic cancer[J].Am J Gastroenterol,2018.[Epub ahead of print]
[40]CERULLO M,GANI F,CHEN S Y,et al.Assessing the financial burden associated with treatment options for resectable pancreatic cancer[J].Ann Surg,2018,267(3):544-551.
[41]SHI S,HUA J,LIANG C,et al.Proposed modification of the8th edition of the AJCC staging system for pancreatic ductal adenocarcinoma[J].Ann Surg,2018.[Epub ahead of print]
[42]van ROESSEL S,KASUMOVA G G,VERHEIJ J,et al.International validation of the eighth edition of the American Joint Committee on Cancer(AJCC)TNM staging system in patients with resected pancreatic cancer[J].JAMA Surg,2018,153(12):e183617.
[43]SHI S,LIANG C,XU J,et al.The strain ratio as obtained by endoscopic ultrasonography elastography correlates with the stroma proportion and the prognosis of local pancreatic cancer[J].Ann Surg,2018.[Epub ahead of print]
[44]TATARIAN T,JIANG W,LEIBY B E,et al.Cytoplasmic HuRstatus predicts disease-free survival in resected pancreatic cancer:a post-hoc analysis from the international phaseⅢESPAC-3 clinical trial[J].Ann Surg,2018,267(2):364-369.
[45]PISHVAIAN M J,BENDER R J,HALVERSON D,et al.Molecular profiling of patients with pancreatic cancer:initial results from the know your tumor initiative[J].Clin Cancer Res,2018,24(20):5018-5027.
[46]AGUIRRE A J,NOWAK J A,CAMARDA N D,et al.Realtime genomic characterization of advanced pancreatic cancer to enable precision medicine[J].Cancer Discov,2018,8(9):1096-1111.
[47]AUNG K L,FISCHER S E,DENROCHE R E,et al.Genomicsdriven precision medicine for advanced pancreatic cancer:early results from the COMPASS trial[J].Clin Cancer Res,2018,24(6):1344-1354.
[48]EDDERKAOUI M,CHHEDA C,SOUFI B,et al.An inhibitor of GSK3B and HDACs kills pancreatic cancer cells and slows pancreatic tumor growth and metastasis in mice[J].Gastroenterology,2018.[Epub ahead of print]
[49]CAMBLIN A J,PACE E A,ADAMS S,et al.Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer[J].Clin Cancer Res,2018,24(12):2873-2885.
[50]WARTENBERG M,CIBIN S,ZLOBEC I,et al.Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance[J].Clin Cancer Res,2018,24(18):4444-4454.
[51]MACE T A,SHAKYA R,PITARRESI J R,et al.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer[J].Gut,2018,67(2):320-332.
[52]MICHAELS A D,NEWHOOK T E,ADAIR S J,et al.CD47 blockade as an adjuvant immunotherapy for resectable pancreatic cancer[J].Clin Cancer Res,2018,24(6):1415-1425.
[53]ZHOU F,YANG J,ZHANG Y,et al.Local phototherapy synergizes with immunoadjuvant for treatment of pancreatic cancer through induced immunogenic tumor vaccine[J].Clin Cancer Res,2018,24(21):5335-5346.
[54]WANG Y N,LEE H H,CHOU C K,et al.Angiogenin/ribonuclease 5 is an EGFR ligand and a serum biomarker for erlotinib sensitivity in pancreatic cancer[J].Cancer Cell,2018,33(4):752-769.
[55]CHOU A,FROIO D,NAGRIAL A M,et al.Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer[J].Gut,2018,67(12):2142-2155.
[56]GILLES M E,HAO L,HUANG L,et al.Personalized RNAmedicine for pancreatic cancer[J].Clin Cancer Res,2018,24(7):1734-1747.
[2]RAHIB L,SMITH B D,AIZENBERG R,et al.Projecting cancer incidence and deaths to 2030:the unexpected burden of thyroid,liver,and pancreas cancers in the United States[J].Cancer Res,2014,74(11):2913-2921.
[3]KIRKEGARD J,CRONIN-FENTON D,HEIDE-JORGENSENU,et al.Acute pancreatitis and pancreatic cancer risk:a nationwide matched-cohort study in Denmark[J].Gastroenterology,2018,154(6):1729-1736.
[4]SADR-AZODI O,OSKARSSON V,DISCACCIATI A,et al.Pancreatic cancer following acute pancreatitis:a populationbased matched cohort study[J].Am J Gastroenterol,2018,113(11):1711-1719.
[5]ANTWI S O,FAGAN S E,CHAFFEE K G,et al.Risk of different cancers among first-degree relatives of pancreatic cancer patients:influence of probands’susceptibility gene mutation status[J].J Natl Cancer Inst,2018.[Epub ahead of print]
[6]JIAO L,CHEN L,WHITE D L,et al.Low-fat dietary pattern and pancreatic cancer risk in the women’s health initiative dietary modification randomized controlled trial[J].J Natl Cancer Inst,2018,110(1).
[7]SHARMA A,SMYRK T C,LEVY M J,et al.Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis[J].Gastroenterology,2018,155(2):490-500.
[8]SETIAWAN V W,STRAM D O,PORCEL J,et al.Pancreatic cancer following incident diabetes in African Americans and Latinos:the multiethnic cohort[J].J Natl Cancer Inst,2018.[Epub ahead of print]
[9]SHARMA A,KANDLAKUNTA H,NAGPAL S,et al.Model to determine risk of pancreatic cancer in patients with new-onset diabetes[J].Gastroenterology,2018,155(3):730-739.
[10]FAN X,ALEKSEYENKO A V,WU J,et al.Human oral microbiome and prospective risk for pancreatic cancer:a population-based nested case-control study[J].Gut,2018,67(1):120-127.
[11]KHALAF N,YUAN C,HAMADA T,et al.Regular use of aspirin or non-aspirin nonsteroidal anti-inflammatory drugs is not associated with risk of incident pancreatic cancer in two large cohort studies[J].Gastroenterology,2018,154(5):1380-1390.
[12]SHEEL A,HARRISON S,SARANTITIS I,et al.Identification of cystic lesions by secondary screening of familial pancreatic cancer(FPC)kindreds is not associated with the stratified risk of cancer[J].Am J Gastroenterol,2018.[Epub ahead of print]
[13]CANTO M I,ALMARIO J A,SCHULICK R D,et al.Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance[J].Gastroenterology,2018,155(3):740-751.
[14]HU C,HART S N,POLLEY E C,et al.Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer[J].JAMA,2018,319(23):2401-2409.
[15]NIMMAKAYALA R K,SESHACHARYULU P,LAKSHMANANI,et al.Cigarette smoke induces stem cell features of pancreatic cancer cells via PAF1[J].Gastroenterology,2018,155(3):892-908.
[16]MUELLER S,ENGLEITNER T,MARESCH R,et al.Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes[J].Nature,2018,554(7690):62-68.
[17]LIU M,YANG J,ZHANG Y,et al.ZIP4 promotes pancreatic cancer progression by repressing ZO-1 and claudin-1 through a ZEB1-dependent transcriptional mechanism[J].Clin Cancer Res,2018,24(13):3186-3196.
[18]ANDRICOVICH J,PERKAIL S,KAI Y,et al.Loss of KDM6Aactivates super-enhancers to induce gender-specific squamouslike pancreatic cancer and confers sensitivity to BET inhibitors[J].Cancer Cell,2018,33(3):512-526.
[19]WANG F,XIA X,YANG C,et al.SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy[J].Clin Cancer Res,2018,24(13):3176-3185.
[20]HENRY K E,DACEK M M,DILLING T R,et al.A PETimaging strategy for interrogating target engagement and oncogene status in pancreatic cancer[J].Clin Cancer Res,2018,25(1):166-176.
[21]HEINING C,HORAK P,UHRIG S,et al.NRG1 fusions in KRAS wild-type pancreatic cancer[J].Cancer Discov,2018,8(9):1087-1095.
[22]DANAI L V,BABIC A,ROSENTHAL M H,et al.Altered exocrine function can drive adipose wasting in early pancreatic cancer[J].Nature,2018,558(7711):600-604.
[23]RENZ B W,TAKAHASHI R,TANAKA T,et al.Beta2 Adrenergic-neurotrophin feedforward loop promotes pancreatic cancer[J].Cancer Cell,2018,33(1):75-90.
[24]LIANG C,SHI S,LIU M,et al.PIN1 maintains redox balance via the c-Myc/NRF2 axis to counteract Kras-induced mitochondrial respiratory injury in pancreatic cancer cells[J].Cancer Res,2019,79(1):133-145.
[25]PUSHALKAR S,HUNDEYIN M,DALEY D,et al.The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression[J].Cancer Discov,2018,8(4):403-416.
[26]BERNARD V,SEMAAN A,HUANG J,et al.Single cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression[J].Clin Cancer Res,2018.[Epub ahead of print]
[27]POMMIER A,ANAPARTHY N,MEMOS N,et al.Unresolved endoplasmic reticulum stress engenders immune-resistant,latent pancreatic cancer metastases[J].Science,2018,360(6394):4908.
[28]YANG A,HERTER-SPRIE G,ZHANG H,et al.Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms[J].Cancer Discov,2018,8(3):276-287.
[29]TIRIAC H,BELLEAU P,ENGLE D D,et al.Organoid profiling identifies common responders to chemotherapy in pancreatic cancer[J].Cancer Discov,2018,8(9):1112-1129.
[30]KNUDSEN E S,BALAJI U,MANNAKEE B,et al.Pancreatic cancer cell lines as patient-derived avatars:genetic characterisation and functional utility[J].Gut,2018,67(3):508-520.
[31]MELLBY L D,NYBERG A P,JOHANSEN J S,et al.Serum biomarker signature-based liquid biopsy for diagnosis of earlystage pancreatic cancer[J].J Clin Oncol,2018,36(28):2887-2894.
[32]FAHRMANN J F,BANTIS L E,CAPELLO M,et al.A plasmaderived protein-metabolite multiplexed panel for early-stage pancreatic cancer[J].J Natl Cancer Inst,2018.[Epub ahead of print]
[33]JABBAR K S,ARIKE L,VERBEKE C S,et al.Highly accurate identification of cystic precursor lesions of pancreatic cancer through targeted mass spectrometry:a phaseⅡc diagnostic study[J].J Clin Oncol,2018,36(4):367-375.
[34]FRANKLIN O,JONSSON P,BILLING O,et al.Plasma microRNA alterations appear late in pancreatic cancer[J].Ann Surg,2018,267(4):775-781.
[35]SANDINI M,PATINO M,FERRONE C R,et al.Association between changes in body composition and neoadjuvant treatment for pancreatic cancer[J].JAMA Surg,2018,153(9):809-815.
[36]HE J,BLAIR A B,GROOT V P,et al.Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?[J].Ann Surg,2018,268(1):1-8.
[37]GEMENETZIS G,GROOT V P,BLAIR A B,et al.Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection[J].Ann Surg,2018.[Epub ahead of print]
[38]JANG J Y,HAN Y,LEE H,et al.Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer:a prospective,randomized,open-label,multicenter phase 2/3trial[J].Ann Surg,2018,268(2):215-222.
[39]MAJUMDER S,PHILIP N A,NAGPAL S,et al.High-grade dysplasia in resected main-duct intraductal papillary mucinous neoplasm(MD-IPMN)is associated with an increased risk of subsequent pancreatic cancer[J].Am J Gastroenterol,2018.[Epub ahead of print]
[40]CERULLO M,GANI F,CHEN S Y,et al.Assessing the financial burden associated with treatment options for resectable pancreatic cancer[J].Ann Surg,2018,267(3):544-551.
[41]SHI S,HUA J,LIANG C,et al.Proposed modification of the8th edition of the AJCC staging system for pancreatic ductal adenocarcinoma[J].Ann Surg,2018.[Epub ahead of print]
[42]van ROESSEL S,KASUMOVA G G,VERHEIJ J,et al.International validation of the eighth edition of the American Joint Committee on Cancer(AJCC)TNM staging system in patients with resected pancreatic cancer[J].JAMA Surg,2018,153(12):e183617.
[43]SHI S,LIANG C,XU J,et al.The strain ratio as obtained by endoscopic ultrasonography elastography correlates with the stroma proportion and the prognosis of local pancreatic cancer[J].Ann Surg,2018.[Epub ahead of print]
[44]TATARIAN T,JIANG W,LEIBY B E,et al.Cytoplasmic HuRstatus predicts disease-free survival in resected pancreatic cancer:a post-hoc analysis from the international phaseⅢESPAC-3 clinical trial[J].Ann Surg,2018,267(2):364-369.
[45]PISHVAIAN M J,BENDER R J,HALVERSON D,et al.Molecular profiling of patients with pancreatic cancer:initial results from the know your tumor initiative[J].Clin Cancer Res,2018,24(20):5018-5027.
[46]AGUIRRE A J,NOWAK J A,CAMARDA N D,et al.Realtime genomic characterization of advanced pancreatic cancer to enable precision medicine[J].Cancer Discov,2018,8(9):1096-1111.
[47]AUNG K L,FISCHER S E,DENROCHE R E,et al.Genomicsdriven precision medicine for advanced pancreatic cancer:early results from the COMPASS trial[J].Clin Cancer Res,2018,24(6):1344-1354.
[48]EDDERKAOUI M,CHHEDA C,SOUFI B,et al.An inhibitor of GSK3B and HDACs kills pancreatic cancer cells and slows pancreatic tumor growth and metastasis in mice[J].Gastroenterology,2018.[Epub ahead of print]
[49]CAMBLIN A J,PACE E A,ADAMS S,et al.Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer[J].Clin Cancer Res,2018,24(12):2873-2885.
[50]WARTENBERG M,CIBIN S,ZLOBEC I,et al.Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance[J].Clin Cancer Res,2018,24(18):4444-4454.
[51]MACE T A,SHAKYA R,PITARRESI J R,et al.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer[J].Gut,2018,67(2):320-332.
[52]MICHAELS A D,NEWHOOK T E,ADAIR S J,et al.CD47 blockade as an adjuvant immunotherapy for resectable pancreatic cancer[J].Clin Cancer Res,2018,24(6):1415-1425.
[53]ZHOU F,YANG J,ZHANG Y,et al.Local phototherapy synergizes with immunoadjuvant for treatment of pancreatic cancer through induced immunogenic tumor vaccine[J].Clin Cancer Res,2018,24(21):5335-5346.
[54]WANG Y N,LEE H H,CHOU C K,et al.Angiogenin/ribonuclease 5 is an EGFR ligand and a serum biomarker for erlotinib sensitivity in pancreatic cancer[J].Cancer Cell,2018,33(4):752-769.
[55]CHOU A,FROIO D,NAGRIAL A M,et al.Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer[J].Gut,2018,67(12):2142-2155.
[56]GILLES M E,HAO L,HUANG L,et al.Personalized RNAmedicine for pancreatic cancer[J].Clin Cancer Res,2018,24(7):1734-1747.